|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
Oncology: EMEA Approval Lags
Author(s)Kevin Gopal
London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.
Advertisement
Articles in this issue
almost 25 years ago
National Crisis Supercedes Coverage Debatealmost 25 years ago
PBMs: Merck-Medco in the Hot Seatalmost 25 years ago
National Crisis Supercedes Coverage Debatealmost 25 years ago
A Five-Year Forecast: Clear Seas Ahead?almost 25 years ago
Weak Bones, Strong Marketalmost 25 years ago
Approvals: Novartis’ Silver Liningalmost 25 years ago
Pfizer and others Pitch Inalmost 25 years ago
Illegal Sales in Indiaalmost 25 years ago
Health Plan Premiums: Pharma Takes the Blamealmost 25 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5